Main points of investment:

(1) Market position. The company focuses on the field of anti-drug-resistant and anti-infective drugs. It has strong competitiveness in the field of new generation penicillin. The company has many advantages and strong competitiveness, the main products mezlocillin sodium sulbactam sodium, amoxicillin sodium sulbactam sodium market share ranked second in the country. In the past three years, the company's operating income grew at a compound rate of 25%, and its net profit grew at a compound rate of 91%.

(2) Anti-infective drugs to solve the problem of bacterial drug resistance are the main growth point of the company. From the domestic penicillin preparation market sales situation, can effectively solve the bacterial drug resistance of semi-synthetic penicillin compound preparation sales are increasing year by year, in 2009 sales amount has accounted for about 46% of penicillin preparation sales. With the increase of market attention to the problem of bacterial drug resistance, semi-synthetic penicillin compound preparation will become the main profit growth point of the company.

(3) the prospect of the fund-raising project. Raise funds to invest: fosfomycin aminobutyriol API project will expand and improve the company's product structure and enhance product competitiveness; R & D center construction project will further improve the company's product R & D capability. The use of funds raised will help the company to increase investment in research and development, break through capacity bottlenecks, and improve the company's overall competitiveness.

Profit Forecast:

It is estimated that the fully diluted EPS in 2011-2013 is 0.45,0.60,0.72 yuan respectively.